JP2022510410A5 - - Google Patents
Info
- Publication number
- JP2022510410A5 JP2022510410A5 JP2021531722A JP2021531722A JP2022510410A5 JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5 JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- composition according
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776985P | 2018-12-07 | 2018-12-07 | |
| US62/776,985 | 2018-12-07 | ||
| US201962909147P | 2019-10-01 | 2019-10-01 | |
| US62/909,147 | 2019-10-01 | ||
| US201962926390P | 2019-10-25 | 2019-10-25 | |
| US62/926,390 | 2019-10-25 | ||
| PCT/US2019/065069 WO2020118252A1 (en) | 2018-12-07 | 2019-12-06 | Methods for treating castration-resistant and castration- sensitive prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510410A JP2022510410A (ja) | 2022-01-26 |
| JP2022510410A5 true JP2022510410A5 (cg-RX-API-DMAC7.html) | 2022-11-29 |
Family
ID=70974424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531722A Pending JP2022510410A (ja) | 2018-12-07 | 2019-12-06 | 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200281949A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3891294A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022510410A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210100145A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164500A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019395100A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120850A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005075A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118252A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| HUE045585T2 (hu) | 2015-05-18 | 2020-01-28 | Tolero Pharmaceuticals Inc | Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
| US20190240198A1 (en) * | 2018-02-05 | 2019-08-08 | Dean G. Tang | Formulations and methods for the treatment of cancers |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| EP4135675A4 (en) | 2020-04-17 | 2024-04-10 | Essa Pharma, Inc. | SOLID FORMS OF AN N-TERMINAL DOMAIN ANDROGEN RECEPTOR INHIBITOR AND USES THEREOF |
| CA3215182A1 (en) * | 2021-04-16 | 2022-10-20 | Han-Jie Zhou | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
| WO2023114264A1 (en) * | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001253618A1 (en) * | 2000-04-21 | 2001-11-07 | Arch Development Corporation | Flavopiridol drug combinations and methods with reduced side effects |
| HK1212683A1 (zh) * | 2012-09-26 | 2016-06-17 | Mannkind Corporation | 多个激酶途径抑制剂 |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| WO2016033114A1 (en) * | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| HUE045585T2 (hu) * | 2015-05-18 | 2020-01-28 | Tolero Pharmaceuticals Inc | Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok |
| WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| US11034710B2 (en) * | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
-
2019
- 2019-12-06 CA CA3120850A patent/CA3120850A1/en active Pending
- 2019-12-06 AU AU2019395100A patent/AU2019395100A1/en not_active Abandoned
- 2019-12-06 WO PCT/US2019/065069 patent/WO2020118252A1/en not_active Ceased
- 2019-12-06 KR KR1020217020796A patent/KR20210100145A/ko not_active Withdrawn
- 2019-12-06 US US16/706,463 patent/US20200281949A1/en not_active Abandoned
- 2019-12-06 EP EP19893131.3A patent/EP3891294A4/en not_active Withdrawn
- 2019-12-06 JP JP2021531722A patent/JP2022510410A/ja active Pending
- 2019-12-06 CN CN201980080943.0A patent/CN113164500A/zh active Pending
- 2019-12-06 MX MX2021005075A patent/MX2021005075A/es unknown
-
2021
- 2021-12-10 US US17/547,799 patent/US20220339172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markman | Managing taxane toxicities | |
| RU2587013C2 (ru) | Комбинированная химиотерапия | |
| JP2019529581A5 (cg-RX-API-DMAC7.html) | ||
| JP2020516646A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517696A5 (cg-RX-API-DMAC7.html) | ||
| JP2012522837A5 (cg-RX-API-DMAC7.html) | ||
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| CN117881396A (zh) | 用螺甾内酯和酰基富烯的组合治疗癌症 | |
| JP2020536055A5 (cg-RX-API-DMAC7.html) | ||
| WO2020051294A1 (en) | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer | |
| KR20240006610A (ko) | 다중-키나제 억제제의 제약 조성물 및 용도 | |
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| JP2025511402A5 (cg-RX-API-DMAC7.html) | ||
| Hainsworth et al. | Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma | |
| CA2525277A1 (en) | Method for augmenting the antitumor activity of anti-cancer agents | |
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 | |
| JP2020517739A (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体2陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| Köppler et al. | Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions | |
| JP2024523123A (ja) | 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用 | |
| AU2024334390A1 (en) | Anti-tumor use of act001 composition | |
| JP2025511403A5 (cg-RX-API-DMAC7.html) | ||
| WO2022165056A1 (en) | Treating cancer in patient with pten inactivating mutation | |
| KR20240046527A (ko) | 암치료를 위한 신규 경구용 약학적 조성물 | |
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 |